Everhart Financial Group Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Everhart Financial Group Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 352 shares of the biopharmaceutical company's stock after selling 508 shares during the period. Everhart Financial Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $251,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Private Wealth Management Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:REGN traded up $4.31 during mid-day trading on Friday, hitting $700.33. The company had a trading volume of 727,332 shares, compared to its average volume of 923,518. The firm has a fifty day moving average price of $699.40 and a 200 day moving average price of $883.75. The company has a market capitalization of $76.56 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.30 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business posted $11.86 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%.

Analysts Set New Price Targets

Several research firms recently commented on REGN. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Finally, Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.